International Journal of Computational and Experimental Science and ENgineering (IJCESEN)

Vol. 10-No.4 (2024) pp. 4118-4124
http://www.ijcesen.com

ISSN: 2149-9144

Research Article

Point-of-Care Testing (POCT) in Emergency and Critical Care Settings: Clinical Outcomes and Laboratory Integration

Naief Mohommad Ali Abdelaal[1]*, Jomanh Hudeeb Alamri[2], Turki Mohammed Sultan Hakami[3], Hakeem Mohammed Alomair[4], Montaha Radhi Qussom Alanazi[5], Abdullah Omar Mohammed Omair[6], Zayed Mohammad Zayed Aldawsari[7], Ziyad Saad Juraybia Alraddadi[8], Faris Hamad Ayed Altait[9], YasirAhmed Mohammed Abduldaem[10]

[1]Laboratory Specialist, Branch of the Ministry of Health – Commitment Management, Ministry of Health, Tabuk, Tabuk Region, Saudi Arabia
* **Corresponding Author Email:** nabdulaal@moh.gov.sa - **ORCID:** 0000-0002-5337-995Y

[2]Laboratory Microbiology Technician, King Fahd General Hospital, Jeddah Health Cluster, Ministry of Health, Jeddah, Makkah Region, Saudi Arabia
Email: jhalamri@moh.gov.sa - **ORCID:** 0000-0002-5007-7388

[3]Specialist Laboratory, Samtah General Hospital, Jazan Health Cluster, Ministry of Health, Samtah, Jazan Region, Saudi Arabia
Email: thakami@moh.gov.sa - **ORCID:** 0000-0002-5007-7377

[4]Laboratory Technician, Al Rass General Hospital, Qassim Health Cluster, Ministry of Health, Al Rass, Qassim Region, Saudi Arabia
Email: hmalomair@moh.gov.sa- **ORCID:** 0000-0002-5007-7366

[5]Laboratory Technologist Specialist, Prince Abdulaziz bin Musaed Hospital, Northern Borders Health Cluster, Ministry of Health, Arar, Northern Borders Region, Saudi Arabia
Email: mralanziy@moh.gov.sa- **ORCID:** 0000-0002-5007-7355

[6]Specialist Laboratory, Clinical Immunology, Regional Laboratory, Madinah Health Cluster, Ministry of Health, Madinah, Madinah Region, Saudi Arabia
Email: aomeer@moh.gov.sa- **ORCID:** 0000-0002-5007-7344

[7]Laboratory Specialist, Marriage Examination Center, Hail Health Cluster, Ministry of Health, Hail, Hail Region, Saudi Arabia
Email: zaldawsari@moh.gov.sa - **ORCID:** 0000-0002-5007-7333

[8]Laboratory Technician, Regional Laboratory, Madinah Health Cluster, Ministry of Health, Madinah, Madinah Region, Saudi Arabia
Email: z1y4d@hotmail.com - **ORCID:** 0000-0002-5007-7322

[9]Laboratory Technician, Hail Health Cluster, Ministry of Health, Hail, Hail Region, Saudi Arabia
Email: falgaite@moh.gov.sa - **ORCID:** 0000-0002-5007-7311

[9]Laboratory Technician – Haql General Hospital – Tabuk Health Cluster – Ministry of Health – Haql – Tabuk Region – Saudi Arabia
Email: yabduldaim@moh.gov.sa - **ORCID:** 0000-0002-5007-7991

Article Info:

DOI: 10.22399/ijcesen.4857
Received : 01 May 2024
Accepted : 30 May 2024

Keywords

Point-of-Care Testing (POCT),
Emergency Medicine,
Critical Care,

Abstract:

Point-of-Care Testing (POCT) has emerged as a transformative paradigm in emergency and critical care medicine, fundamentally altering the diagnostic timeline by delivering crucial laboratory results at the patient's bedside within minutes rather than hours. This capability for rapid clinical decision-making directly enhances the management of time-sensitive conditions such as acute coronary syndromes, septic shock, major trauma, and life-threatening metabolic imbalances, ultimately contributing to improved patient outcomes through earlier intervention and more dynamic treatment guidance. However, the integration of POCT into these high-stakes environments extends beyond technological deployment, necessitating a robust framework of laboratory stewardship

Clinical Outcomes,
Turnaround Time (TAT),
Laboratory Integration

to ensure analytical reliability. Successful implementation hinges on a multidisciplinary approach that addresses stringent quality management, comprehensive operator training, seamless data connectivity with electronic health records, and a holistic assessment of cost-effectiveness that values clinical efficiency gains alongside per-test costs. The future of POCT points toward even greater integration through multiplexed syndromic panels, continuous monitoring, and artificial intelligence, yet its enduring value and safety remain contingent upon its systematic governance as an indispensable component of a unified, patient-centered diagnostic strategy.

1. Introduction

The landscape of modern medicine, particularly within the high-stakes environments of the emergency department (ED) and the intensive care unit (ICU), is perpetually challenged by the critical nexus of time, accuracy, and clinical decision-making. In these arenas, where patient physiology can deteriorate with alarming rapidity, the traditional paradigm of central laboratory testing—with its inherent delays due to sample transportation, processing, and result reporting—often presents a significant bottleneck. This temporal disconnect between the onset of a pathological state and its biochemical confirmation can impede timely intervention, potentially compromising patient outcomes. It is within this context that Point-of-Care Testing (POCT) has emerged not merely as a technological adjunct but as a transformative operational philosophy. Defined as diagnostic testing performed at or near the site of patient care, with the result leading to a potential change in the management of that patient, POCT promises to collapse the diagnostic timeline, bringing the laboratory to the bedside [1].

The conceptual roots of POCT are ancient, from the physician tasting urine for glucose, but its modern incarnation is a product of late 20th and early 21st-century technological revolutions. The development of miniaturized sensors, sophisticated biosensors, microfluidics, and robust immunoassay platforms has enabled the creation of devices that are both highly accurate and remarkably user-friendly. Today, POCT encompasses a vast array of analytes, from fundamental parameters like blood glucose and arterial blood gases (ABGs) to complex biomarkers such as cardiac troponins, brain natriuretic peptide (BNP), lactate, and even molecular diagnostics for infectious diseases like influenza and SARS-CoV-2 [2]. The diffusion of this technology into emergency and critical care has been driven by an overarching goal: to convert diagnostic data into actionable clinical intelligence with minimal latency, thereby supporting the "golden hour" and "platinum ten minutes" principles that are cornerstones of resuscitation and acute care medicine.

The theoretical benefits of POCT in these settings are profound and multi-faceted. Foremost is the dramatic reduction in turnaround time (TAT). While central laboratory TAT can range from 60 minutes to several hours for certain tests, POCT can deliver results in a matter of minutes—sometimes even seconds. This acceleration can expedite critical diagnoses, such as acute myocardial infarction (AMI) or severe sepsis, enabling earlier initiation of life-saving therapies like percutaneous coronary intervention or appropriate antibiotics and resuscitation bundles [3]. Furthermore, the compact nature of POCT devices facilitates more frequent monitoring, allowing for dynamic, real-time assessment of a patient's response to treatment. For instance, serial lactate measurements via POCT can guide the efficacy of septic shock resuscitation, while repeated ABG analyses can fine-tune mechanical ventilation strategies in acute respiratory distress syndrome (ARDS) patients [4]. This capability fosters a more responsive and personalized approach to critical care.

Beyond speed, POCT enhances workflow efficiency by reducing pre-analytical errors associated with sample handling and transport. It also has the potential to improve patient throughput in overcrowded EDs by shortening the decision-making loops for disposition—admission, discharge, or transfer. Moreover, from a patient-centered perspective, immediate testing and subsequent discussion of results can improve communication and satisfaction [5]. However, the integration of POCT into the complex ecosystem of emergency and critical care is not without formidable challenges. These challenges form the critical counterpoint to its promised benefits and must be rigorously addressed to realize its full potential. The decentralized nature of testing raises significant concerns regarding quality assurance, operator competency, and data management. Ensuring that a POCT result generated by a nurse or emergency physician at 3:00 AM is as reliable as one produced by a certified medical technologist in a controlled laboratory environment is paramount [6].

This necessitates robust governance structures, involving strict adherence to regulatory standards (e.g., CLIA in the United States, ISO 22870 internationally), comprehensive training and certification programs for operators, and rigorous internal and external quality control (QC) and

proficiency testing (PT) protocols. Furthermore, the seamless integration of POCT data into the patient's electronic health record (EHR) is essential to avoid creating information silos and to ensure that all care providers are working from a unified, accurate dataset. The economic evaluation of POCT is also complex, requiring a holistic view beyond the per-test cartridge cost to encompass its impact on overall hospital length of stay, complication rates, and resource utilization [7, 8].

2. Clinical Outcomes in Emergency and Critical Care

2.1 Cardiac Emergencies: Accelerating the Ischemic Cascade

The management of acute coronary syndromes (ACS), particularly ST-elevation myocardial infarction (STEMI), is fundamentally a race against time. Every minute of delay in reperfusion correlates with increased myocardial necrosis and worse long-term mortality. POCT for cardiac biomarkers, specifically high-sensitivity cardiac troponin (hs-cTn) and to a lesser extent, creatine kinase-MB (CK-MB) and myoglobin, has revolutionized triage and decision-making in chest pain patients. The ability to obtain a troponin result within 10-15 minutes at the bedside allows for extremely rapid rule-in or rule-out protocols.

Studies have consistently demonstrated that POCT-guided pathways significantly reduce the time to diagnosis and treatment. In the ED, this can decrease the door-to-balloon time for STEMI patients by expediting activation of the catheterization laboratory, even before formal central lab confirmation. For non-STEMI (NSTEMI) patients, rapid troponin results facilitate earlier risk stratification, allowing for prompt initiation of antiplatelet and anticoagulant therapy and timely transfer to a coronary care unit or intervention suite [9]. Furthermore, the development of validated rapid rule-out algorithms, often utilizing a single baseline hs-cTn measurement below a very low threshold or a 0/1-hour serial sampling protocol with POCT, has enabled the safe and efficient discharge of low-risk patients from the ED. This reduces unnecessary hospital admissions, alleviates ED crowding, and lowers healthcare costs without compromising patient safety [10]. Beyond troponin, POCT for B-type natriuretic peptide (BNP) or N-terminal pro-BNP (NT-proBNP) provides immediate value in differentiating acute dyspnea, aiding in the rapid diagnosis of acute heart failure amidst other causes like COPD exacerbation or pneumonia, thereby guiding appropriate diuretic and vasodilator therapy.

2.2 Sepsis and Septic Shock: Guiding the Resuscitation Bundle

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, demands urgent, protocolized management. The Surviving Sepsis Campaign guidelines emphasize early recognition, timely administration of broad-spectrum antibiotics, and rapid hemodynamic resuscitation. POCT serves as a powerful enabler for each of these pillars. Lactate measurement is a cornerstone of sepsis management, with hyperlactatemia (>2 mmol/L) indicating tissue hypoperfusion and being a key criterion for septic shock. POCT lactate meters provide results within seconds from a small blood sample, allowing for immediate identification of high-risk patients and serial monitoring to guide resuscitation endpoints. Early lactate clearance, facilitated by goal-directed therapy, is associated with improved survival, and POCT makes this dynamic assessment feasible at the bedside [11].

Similarly, POCT for biomarkers like procalcitonin (PCT), although more debated, can assist in the early diagnosis of bacterial infection and later guide the duration of antibiotic therapy, supporting antimicrobial stewardship efforts. The integration of these rapid tests into sepsis screening protocols (e.g., nurse-initiated lactate testing for patients with suspected infection) can significantly shorten the time to bundle compliance. Furthermore, POCT for blood gases and electrolytes provides instant feedback on acid-base status, oxygenation, and electrolyte imbalances common in severe sepsis, allowing for precise titration of ventilatory support, fluids, and inotropes [12]. The aggregate effect of these point-of-care tools is a more agile, data-driven, and timely response to one of the most time-critical conditions in medicine.

2.3 Trauma and Major Hemorrhage: The Role of Viscoelastic Testing

The management of major trauma, especially in the context of hemorrhagic shock, requires rapid assessment of coagulation status to guide targeted transfusion therapy. Traditional laboratory tests like prothrombin time (PT), activated partial thromboplastin time (aPTT), and fibrinogen level have a TAT that is often incompatible with the pace of exsanguination. Furthermore, they provide limited insight into the full dynamics of clot formation and stability. This gap has been filled by Point-of-Care Viscoelastic Hemostatic Assays

(VHA), such as thromboelastography (TEG) and rotational thromboelastometry (ROTEM).

These devices provide a real-time, graphic representation of the entire clotting process—from initial fibrin formation and platelet interaction to clot strength and eventual lysis—from a single whole blood sample. In the trauma bay or ICU, VHA allows for the rapid diagnosis of specific coagulopathies: hypofibrinogenemia, platelet dysfunction, hyperfibrinolysis, or heparin effect. This enables a goal-directed, "precision transfusion" strategy, tailoring the administration of fresh frozen plasma, cryoprecipitate, platelets, and tranexamic acid to the patient's actual hemostatic deficit, rather than relying on fixed-ratio massive transfusion protocols [13]. Multiple observational and some randomized controlled trials have demonstrated that VHA-guided transfusion strategies in trauma and cardiac surgery are associated with reduced overall blood product utilization, decreased incidence of massive transfusion, and potentially improved survival. By preventing both under-transfusion and the risks of over-transfusion (e.g., transfusion-related acute lung injury, volume overload), POCT VHA represents a paradigm shift in hemostatic resuscitation [14].

2.4 Metabolic and Electrolyte Imbalances: Immediate Correction

Critically ill patients are prone to rapid and life-threatening shifts in metabolic and electrolyte homeostasis. Diabetic ketoacidosis (DKA), severe hyponatremia, hyperkalemia, and disorders of calcium and magnesium are common in the ED and ICU. POCT for blood glucose is the oldest and most ubiquitous form of POCT, essential for the safe management of DKA and hyperglycemic hyperosmolar state, allowing for frequent titration of insulin infusion. Similarly, POCT for blood gases invariably includes simultaneous measurement of sodium, potassium, ionized calcium, and sometimes chloride and magnesium.

The immediate availability of these values is crucial. For example, the detection of severe hyperkalemia (>6.5 mmol/L) with associated electrocardiogram changes demands immediate treatment with calcium, insulin/dextrose, and salbutamol. Waiting for a central lab potassium result could be fatal. In patients with renal failure or on dialysis, rapid potassium results guide the urgency and duration of treatment. Ionized calcium is vital in managing massive transfusions, pancreatitis, and septic shock, where hypocalcemia can impair cardiac function and coagulation. The ability to correct these abnormalities in real-time, based on instant POCT results, supports hemodynamic stability and prevents complications [15].

2.5 Coagulation Monitoring for Anticoagulation Therapy

In patients on therapeutic anticoagulation, particularly those with mechanical heart valves, atrial fibrillation, or venous thromboembolism, rapid assessment of coagulation status is frequently needed before urgent procedures or in cases of suspected bleeding or overdose. POCT for activated clotting time (ACT) is standard during cardiopulmonary bypass and percutaneous coronary interventions to monitor high-dose heparin therapy. For patients on vitamin K antagonists (e.g., warfarin), POCT devices for prothrombin time/international normalized ratio (PT/INR) enable immediate dosage adjustment in anticoagulation clinics or prior to procedures, improving patient convenience and therapeutic control.

Perhaps the most significant advancement is the use of POCT for direct oral anticoagulant (DOAC) levels. While not yet routine, emerging POCT devices capable of measuring anti-Factor Xa activity (for rivaroxaban, apixaban, edoxaban) or dilute thrombin time (for dabigatran) are becoming available. In the emergency setting for a bleeding patient on a DOAC, such a test could instantly confirm the presence and approximate level of the drug, guiding the use and dosing of specific reversal agents like idarucizumab or andexanet alfa. This moves management from empirical to evidence-based reversal, optimizing hemostatic outcomes and conserving expensive reversal agents [16].

3. Laboratory Integration and Governance

3.1 The Central Laboratory's Role: From Competitor to Steward

The proliferation of POCT can create tension with the central laboratory, perceived as a threat to its volume and control. However, the most effective model is one of integration, where the central laboratory transitions from a mere service provider to the overarching steward of all testing—centralized and decentralized. This laboratory stewardship is critical for ensuring the accuracy, reliability, and clinical validity of every test result reported, regardless of its origin. The laboratory, with its expertise in analytical techniques, quality control, and regulatory compliance, is uniquely positioned to manage the POCT program [17]. This stewardship model involves the establishment of a

multidisciplinary POCT committee, typically led by the laboratory director and including representatives from clinical departments (ED, ICU, nursing), administration, and information technology. This committee sets policies, evaluates and selects devices, approves testing menus, and oversees the entire POCT operation.

3.2 Quality Management System: Ensuring Result Reliability

A robust Quality Management System (QMS) is the non-negotiable foundation of any safe POCT program. This system must be as rigorous as that of the central lab and is often mandated by accreditation bodies like The Joint Commission or College of American Pathologists, guided by the ISO 22870 standard. Key components include: 1) **Operator Training and Competency Assessment:** All users must undergo initial training on the specific device, including principles of operation, sample collection, instrument handling, and troubleshooting. Competency must be formally assessed and documented annually, not just assumed. 2) **Internal Quality Control (IQC):** Devices must run control materials with known values at defined frequencies (e.g., every 24 hours of operation, with each new lot of reagents, after maintenance) to verify the analyzer is functioning within specified limits. 3) **External Quality Assessment (EQA)/Proficiency Testing (PT):** The POCT program must participate in formal PT schemes where unknown samples are tested and results are reported to an independent agency for comparison with peer laboratories. This is the ultimate test of analytical accuracy. 4) **Documentation and Record Keeping:** All activities—patient results, QC data, maintenance, operator training records—must be meticulously documented and readily available for audits [18].

3.3 Connectivity and Data Management: The Digital Backbone

A disconnected POCT device is a major patient safety risk. Manual transcription of results into the EHR is error-prone and fails to provide real-time data access to the entire care team. Therefore, bidirectional connectivity between POCT devices and the hospital's Laboratory Information System (LIS) and EHR is essential. Modern POCT devices should feature automated data transfer: when a test is performed, the result, along with operator ID, device ID, sample ID, and QC status, is wirelessly transmitted directly into the patient's record. This eliminates transcription errors, ensures data integrity, and provides an audit trail. Furthermore, connectivity allows the central laboratory to remotely monitor POCT devices in real-time, checking QC status, usage patterns, and error logs, enabling proactive management and support [19]. This digital integration is the backbone that transforms a standalone device into a coherent part of the hospital's diagnostic infrastructure.

3.4 Economic Considerations: Total Cost of Ownership

The economic assessment of POCT is nuanced. A simplistic comparison of the per-test cartridge cost of POCT versus the reagent cost of a central lab test is misleading. A true cost-effectiveness analysis must adopt a "total cost of ownership" perspective. This includes capital equipment costs, maintenance contracts, reagent costs, and the labor costs associated with operator training and QC performance. More importantly, it must account for clinical outcome benefits that translate into economic value: reduced length of stay in the ED or ICU, decreased rates of complications (e.g., renal failure in sepsis, bleeding in trauma), more efficient use of blood products, and potentially shorter overall hospital stays. For example, a POCT troponin pathway that safely discharges low-risk patients 2 hours faster can free up valuable ED beds. A VHA-guided transfusion protocol that reduces platelet and plasma use by 20% generates significant savings. Therefore, the business case for POCT should be built on its value in improving care efficiency and patient outcomes, not just on a narrow cost-per-test analysis [20].

4. Future Directions and Innovations

The trajectory of POCT points towards greater sophistication, integration, and breadth. **Multiplexing Panels** are a key trend, where a single cartridge can test for a suite of biomarkers relevant to a specific clinical syndrome. For instance, a "sepsis panel" might simultaneously quantify PCT, lactate, CRP, and interleukin-6 from one sample. A "respiratory panel" could identify multiple viral and bacterial pathogens. This comprehensive snapshot accelerates syndromic diagnosis [21]. **Non-Invasive and Continuous Monitoring** represents another frontier. Technologies for transcutaneous measurement of gases, continuous glucose monitoring, and even spectroscopic analysis of blood components through the skin aim to provide truly real-time, dynamic physiological data without the need for repeated blood draws [22].

Artificial Intelligence (AI) and Machine Learning will increasingly be embedded in POCT

devices and the interpretation of their results. AI algorithms can integrate multiple POCT results with vital signs and EHR data to provide diagnostic probabilities, risk scores, or treatment recommendations directly to the clinician. For example, an AI model could analyze POCT troponin, ECG, and patient history to calculate a real-time probability of ACS [23]. Finally, the rise of **Telemedicine and Remote Care** is extending POCT into the community and pre-hospital setting. Ambulances equipped with POCT devices (e.g., for troponin, lactate, INR) can transmit results to the receiving hospital, activating specialist teams before patient arrival. In remote clinics, POCT connected via telehealth to a central laboratory expert can bring advanced diagnostics to underserved populations [24].

5. Conclusion

Point-of-Care Testing has irrevocably altered the diagnostic tempo of emergency and critical care medicine. By delivering critical biochemical and hematological data at the bedside within minutes, it empowers clinicians to make faster, more informed decisions that align with the urgent pathophysiology of acute illness. The evidence across cardiac care, sepsis management, trauma resuscitation, and metabolic control demonstrates tangible benefits in reducing time-to-diagnosis, streamlining therapeutic interventions, optimizing resource use, and ultimately, improving patient outcomes. However, the powerful advantages of speed and convenience are inextricably linked to the imperative of accuracy and reliability. Unregulated, poorly managed POCT poses a significant risk of erroneous results that could lead to misdiagnosis and harm.

Therefore, the successful implementation of POCT is not merely a procurement exercise but a comprehensive organizational commitment. Its full potential is only realized through deliberate and strategic integration under the stewardship of the central laboratory, enforced by a rigorous quality management system, enabled by seamless data connectivity, and justified by a holistic value-based assessment. As technology advances towards multiplex panels, continuous monitoring, and AI-enhanced interpretation, the role of POCT will only expand. The future of acute care diagnostics lies in a fully integrated model where rapid, precise, bedside testing and the deep analytical expertise of the central laboratory function in synergistic harmony. In this model, POCT becomes the agile, frontline sensor network, while the laboratory provides the governance, quality framework, and interpretative depth, together forming a cohesive diagnostic engine designed to support the highest standards of care for the most critically ill patients.

Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.
- **Use of AI Tools:** The author(s) declare that no generative AI or AI-assisted technologies were used in the writing process of this manuscript.

References

[1] Kazmierczak SC, Morosyuk S, Rajkumar R. Evaluation of Preanalytical Point-of-Care Testing Errors and Their Impact on Productivity in the Emergency Department in the United States. J Appl Lab Med. 2022 May 04;7(3):650-660.

[2] Gupta N, Augustine S, Narayan T, O'Riordan A, Das A, Kumar D, Luong JHT, Malhotra BD. Point-of-Care PCR Assays for COVID-19 Detection. Biosensors (Basel). 2021 May 01;11(5).

[3] Nichols JH. Utilizing Point-of-Care Testing to Optimize Patient Care. EJIFCC. 2021 Jun;32(2):140-144.

[4] Haleyur Giri Setty MK, Lee S, Lathrop J, Hewlett IK. Biotin Interference in Point of Care HIV Immunoassay. Biores Open Access. 2020;9(1):243-246.

[5] Kost GJ, Ehrmeyer SS, Chernow B, Winkelman JW, Zaloga GP, Dellinger RP, Shirey T. The laboratory-clinical interface: point-of-care testing. Chest. 1999 Apr;115(4):1140-54.

[6] Hayden O, Luppa PB, Min J. Point-of-care testing-new horizons for cross-sectional technologies and decentralized application strategies. Anal Bioanal Chem. 2022 Apr;414(10):3161-3163.

[7] Giannuzzi V, Ruggieri L, Conte R, Manfredi C, Felisi M, Kubiak C, Matei M, Malik S, Demotes J, Ceci A, Bonifazi D. PedCRIN tool for the biosamples management in pediatric clinical trials. Clin Transl Sci. 2023 May;16(5):797-809.

[8] O'Hara M, Wheatley EG, Kazmierczak SC. The Impact of Undetected In Vitro Hemolysis or Sample Contamination on Patient Care and Outcomes in Point-of-Care Testing: A Retrospective Study. J Appl Lab Med. 2020 Mar 01;5(2):332-341.

[9] Hoffman MSF, McKeage JW, Xu J, Ruddy BP, Nielsen PMF, Taberner AJ. Minimally invasive capillary blood sampling methods. Expert Rev Med Devices. 2023 Jan;20(1):5-16.

[10] Schifman RB, Nguyen TT, Page ST. Reliability of point-of-care capillary blood glucose measurements in the critical value range. Arch Pathol Lab Med. 2014 Jul;138(7):962-6.

[11] Astles JR, Stang H, Alspach T, Mitchell G, Gagnon M, Bosse D. CLIA requirements for proficiency testing: the basics for laboratory professionals. MLO Med Lab Obs. 2013 Sep;45(9):8-10, 12, 14-5; quiz 16.

[12] Price CP. Point of care testing. BMJ. 2001 May 26;322(7297):1285-8.

[13] Kost GJ, Jammal MA, Ward RE, Safwat AM. Monitoring of ionized calcium during human hepatic transplantation. Critical values and their relevance to cardiac and hemodynamic management. Am J Clin Pathol. 1986 Jul;86(1):61-70.

[14] Herbin SR, Klepser DG, Klepser ME. Pharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests. J Clin Microbiol. 2020 Apr 23;58(5).

[15] Ferreira CES, Guerra JCC, Slhessarenko N, Scartezini M, Franca CN, Colombini MP, Berlitz F, Machado AMO, Campana GA, Faulhaber ACL, Galoro CA, Dias CM, Shcolnik W, Martino MDV, Cesar KR, Sumita NM, Mendes ME, Faulhaber MHW, Pinho JRR, Barbosa IV, Batista MC, Khawali C, Pariz VM, Andriolo A. Point-of-Care Testing: General Aspects. Clin Lab. 2018 Jan 01;64(1):1-9.

[16] Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM, Jahanshahi-Anbuhi S. Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clin Microbiol Rev. 2021 Jun 16;34(3).

[17] Moeller ME, Engsig FN, Bade M, Fock J, Pah P, Soerensen AL, Bang D, Donolato M, Benfield T. Rapid Quantitative Point-Of-Care Diagnostic Test for Post COVID-19 Vaccination Antibody Monitoring. Microbiol Spectr. 2022 Apr 27;10(2):e0039622.

[18] Montagnana M, Caputo M, Giavarina D, Lippi G. Overview on self-monitoring of blood glucose. Clin Chim Acta. 2009 Apr;402(1-2):7-13.

[19] Tran NK, LaValley C, Bagley B, Rodrigo J. Point of care blood glucose devices in the hospital setting. Crit Rev Clin Lab Sci. 2023 Jun;60(4):290-299.

[20] Ndateva I, Schwandt M, Saewyc E, Sin D, Tobias E, Wong S, Haase K, Ranger M. Participants' experience in using a point of Care Rapid Antigen Test (RAT) for SARS-CoV-2. Ann Fam Med. 2022 Apr 01;20(20 Suppl 1).

[21] Krasowski MD. Educational Case: Hemolysis and Lipemia Interference With Laboratory Testing. Acad Pathol. 2019 Jan-Dec;6:2374289519888754.

[22] Allardet-Servent J, Lebsir M, Dubroca C, Fabrigoule M, Jordana S, Signouret T, Castanier M, Thomas G, Soundaravelou R, Lepidi A, Delapierre L, Penaranda G, Halfon P, Seghboyan JM. Point-of-Care Versus Central Laboratory Measurements of Hemoglobin, Hematocrit, Glucose, Bicarbonate and Electrolytes: A Prospective Observational Study in Critically Ill Patients. PLoS One. 2017;12(1):e0169593.

[23] Carroll KC. Tests for the diagnosis of Clostridium difficile infection: the next generation. Anaerobe. 2011 Aug;17(4):170-4.

[24] Azar MM, Landry ML. Detection of Influenza A and B Viruses and Respiratory Syncytial Virus by Use of Clinical Laboratory Improvement Amendments of 1988 (CLIA)-Waived Point-of-Care Assays: a Paradigm Shift to Molecular Tests. J Clin Microbiol. 2018 Jul;56(7).